Gene fusions involving the Neurotrophic tropomyosin receptor kinase (NTRK) gene occur in less than 1% of NSCLC patients and affect the MEK/ERK and PI3K/AKT pathways, which play a role in cell proliferation, migration, and chemotherapy-induced apoptosis. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.